ArticleRespiration; international review of thoracic diseases2025
Understanding the Growing Burden of Malignant Pleural Effusion - Epidemiology, Healthcare Utilization, and Cost: A Canadian Perspective.
Article in Respiration; international review of thoracic diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The cancer ratio plus in the differential diagnosis of pleural effusions: a scoping review of current evidence.Biochemia medica · 2026Article
- Indwelling peritoneal and pleural catheters in the management of malignant and non-malignant ascites and pleural effusion: experiences from a Danish tertiary center.European clinical respiratory journal · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMalignant pleural effusion (MPE) is common in advanced malignancy. Data are needed on healthcare utilization and costs.
methodsThis population-based retrospective cohort study included patients aged ≥18 years with an MPE diagnosed between January 1, 2004, and December 31, 2018. We described the incidence and prevalence of MPE from 2004 to 2018 and trends in hospital admissions, emergency department (ED) visits, and pleural-based procedures. In patients diagnosed with MPE from 2006 to 2016, we estimated 2-year healthcare costs (2018 US dollars) from the public payer perspective.
resultsThe annual incidence and prevalence of MPE increased from 5,090 and 14,579 in 2004 to 6,977 and 23,204 in 2018, respectively. Annual mortality among prevalent patients decreased from 32% to 28%. In 2004, 57% of patients were hospitalized, decreasing to 50% in 2018. ED visits increased (59%-61%). From 2004 to 2018, the number of patients who had insertions of thoracostomy tube (2,211-3,664) and tunneled pleural catheter (383-1,164) increased. The number of patients receiving pleurodesis declined (565-284). No change occurred in the number of patients receiving video-assisted thoracoscopy (range 140-208/year). Between 2004 and 2016, 76,190 patients were diagnosed with MPE (mean age 71.2; 52% female). The median (interquartile range) healthcare cost during follow-up was USD 45,641 (USD 23,237-USD 86,700), with USD 19,753 (USD 9,590-USD 38,746) for inpatient hospitalization.
conclusionHospitalization and temporizing MPE procedures are associated with high costs. This population-based study may guide clinicians and policymakers to improve MPE management and reduce healthcare costs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.